The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival
Open accessAbstract
Purpose: Alpha-fetoprotein (AFP) is considered to be an indicator of tumor activity in hepatocellular carcinoma (HCC). We present a novel correlation of AFP response to radiologic response, time-to-progression (TTP), progression-free survival (PFS), and overall survival (OS) in patients treated with locoregional therapies. Patients and Methods: Four hundred sixty-three patients with HCC were treated with chemoembolization or radioembolization at our institution. One hundred twenty-five patients with baseline AFP higher than 200 ng/mL were studied for this analysis. AFP response was defined as more than 50% decrease from baseline. One hundred nineteen patients with follow-up imaging were studied for the AFP imaging correlation analysis. AFP response was correlated to radiologic response, TTP, PFS, and OS. Multivariate analyses were performed. Results: Eighty-one patients (65%) showed AFP response. AFP response was seen in 26 (55%) of 47 and 55 (70%) of 78 of patients treated with chemoembolization and radioembolization, respectively (P = .12). WHO response was seen in 41 (53%) of 77 and 10 (24%) of 42 of AFP responders and nonresponders, respectively (P = .002). The hazard ratio (HR) for TTP in AFP nonresponders compared with responders was 2.8 (95% CI, 1.5 to 5.1). The HR for PFS was 4.2 (95% CI, 2.4 to 7.2) in AFP nonresponders compared with responders. The HR for OS in AFP nonresponders compared with responders was 5.5 (95% CI, 3.1 to 9.9) and 2.7 (95% CI, 1.6 to 4.6) on univariate and multivariate analyses, respectively. Conclusion: The data presented support the use of AFP response seen after locoregional therapy as an ancillary method of assessing tumor response and survival, as well as an early objective screening tool for progression by imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cited by
Salem, R., Lewandowski, R. J., Kulik, L., Wang, E., Riaz, A., Ryu, R. K., Sato, K. T., Gupta, R., Nikolaidis, P., Miller, F. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.049 · Cited by 650
Self-citationBiology and significance of alpha-fetoprotein in hepatocellular carcinoma
Galle, P. R., Foerster, F., Kudo, M., Chan, S. L., Llovet, J. M., Qin, S., Schelman, W. R., Chintharlapalli, S., Abada, P. B., Sherman, M., et al. (2019) · Liver International · doi:10.1111/liv.14223 · Cited by 597
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Piñero, F., Dirchwolf, M., & Pessôa, M. G. (2020) · Cells · doi:10.3390/cells9061370 · Cited by 498
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma
Geschwind, J. F. H., Salem, R., Carr, B. I., Soulen, M. C., Thurston, K. G., Goin, K. A., van Buskirk, M., Roberts, C. A., & Goin, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.034 · Cited by 355
Self-citation
Metadata
- Authors
- Riaz, A., Ryu, R. K., Kulik, L. M., Mulcahy, M. F., Lewandowski, R. J., Minocha, J., Ibrahim, S. M., Sato, K. T., Baker, T., Miller, F. H., Newman, S., Omary, R., Abecassis, M., Benson, A. B., & Salem, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-12-01
- Volume
- 27
- Issue
- 34
- Pages
- 5734-5742
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100930626
- Cited by
- 220
- References
- 1
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival. https://app.cochat.ai/papers/10.1200/jco.2009.23.1282
- The paper
- Riaz, A., Ryu, R. K., Kulik, L. M., Mulcahy, M. F., Lewandowski, R. J., Minocha, J., Ibrahim, S. M., Sato, K. T., Baker, T., Miller, F. H., Newman, S., Omary, R., Abecassis, M., Benson, A. B., & Salem, R. (2009). Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.23.1282
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.